

9. The mixed sequence nuclease resistant oligonucleotide or oligonucleotide analog of claim 17, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy, alkylamino or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by alkyloxy.

10. The mixed sequence nuclease resistant oligonucleotide or oligonucleotide analog of claim 17, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by methoxy.

REMARKS

Substitute pages 101 to 107 are provided to comply with the Sequence Rules set forth in 37 CFR § 1.821-1.825. In addition, the paper copy of the Sequence Listing included herein is identical to the last-filed computer readable form (CRF) filed in application Serial No. 08/471,973. Accordingly, no new matter has been added.

Conclusion

Applicants submit that the claims are in condition for allowance, and an early Office Action to that effect is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Respectfully submitted,

Date: November 28, 2001

Jane Inglese
Jane E. Inglese
Registration No. 48,444

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The first paragraph of the specification has been deleted and replaced with the new paragraph shown above.

The Sequence Listing has been deleted and replaced with a new Sequence Listing.

Claims 1 to 7 have been cancelled and new claims 8 to 10 have been added.